^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    1d
    A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    2d
    A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov)
    P2, N=60, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    5d
    Computational exploration of quercetin derivatives from Azadirachta indica leaf as threonine tyrosine kinase inhibitors for potential lung and pancreatic cancer treatment. (PubMed, Comput Biol Chem)
    Quercetin-3-rhamnoside, quercetin-3-glucoside, quercetin-3-O-galactoside, and quercetin-3-rutinoside demonstrated superior binding affinities (-9.5 to -11.089 kcal/mol) compared to control drug Luvixasertib (-8.869 kcal/mol), with enhanced electronic properties (electrophilicity index: 3.53-4.67 compared to control 2.70)...Additionally, toxicity profiling revealed favorable safety profiles with no hepatotoxic, carcinogenic, or mutagenic potential for most derivatives. Therefore, Quercetin derivatives from A. indica leaf represent promising lead compounds for targeted TTK inhibitors in lung and pancreatic adenocarcinomas, highlighting their potential for further experimental validation against TTK.
    Journal
    |
    TTK (TTK Protein Kinase)
    |
    luvixasertib (CFI-402257)
    6d
    GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, University of Arizona
    New P1 trial
    |
    irinotecan
    6d
    Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications. (PubMed, Clin Cancer Res)
    Comprehensive genomic profiling is essential for patients with PAAD and carries both prognostic and predictive value. MTAP loss KRAS-mutant PAAD represents a subgroup of immune-excluded PAADs with a poor prognosis.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • MTAP (Methylthioadenosine Phosphorylase)
    |
    KRAS mutation • KRAS G12D • MTAP deletion • KRAS G12
    |
    BostonGene Tumor Portrait™ Test
    6d
    Durable response to selpercatinib in HOOK3-RET fusion positive, α-fetoprotein producing metastatic pancreatic ductal adenocarcinoma with intestinal-type differentiation. (PubMed, Oncol Lett)
    The patient did not respond to gemcitabine and cisplatin-based systemic chemotherapy. Selpercatinib, a selective inhibitor of receptor tyrosine kinase RET, blocks RET kinase activity by binding to its adenosine triphosphate-binding site, thus preventing the kinase from phosphorylating substrates and halting oncogenic signaling. The patient was treated with selpercatinib, which produced a durable response lasting over 15 months in this chemotherapy-refractory patient, highlighting the efficacy of selpercatinib in HOOK3-RET fusion-positive pancreatic cancer.
    Journal
    |
    RET (Ret Proto-Oncogene) • AFP (Alpha-fetoprotein)
    |
    RET fusion • RET positive
    |
    cisplatin • gemcitabine • Retevmo (selpercatinib)
    7d
    Multi-Omics and Single-Cell Dissection Reveals EXT1 as a Glycosylation-Linked Therapeutic Target in Cancer. (PubMed, Oncol Res)
    It functions as a driver of stromal activation, immune checkpoint engagement, and tumor progression. EXT1 represents a clinically relevant biomarker and a promising therapeutic target in inflammation-driven cancers like PAAD and LUAD.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TGFB1 (Transforming Growth Factor Beta 1) • EXT1 (Exostosin Glycosyltransferase 1)
    7d
    CPSM: An R Package for Cancer Patient Survival Risk Model Using Transcriptomics and Clinical Data. (PubMed, Gigascience)
    Its integrated visual tools enhance interpretability and support more informed clinical decision-making. The package is freely available on Bioconductor (https://bioconductor.org/packages/devel/bioc/html/CPSM.html) and GitHub (https://github.com/hks5august/CPSM).
    Clinical data • Journal
    |
    BRCA (Breast cancer early onset)
    7d
    YARS2 mediates PARPi resistance in pancreatic cancer by regulating the MYC-E2F axis. (PubMed, Acta Histochem)
    Our findings reveal that YARS2 mediates PARPi resistance via the MYC/E2F1 pathway in PDAC, highlighting YARS2 may serve as a potential target for therapy to counteract PARPi resistance.
    Journal • PARP Biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • E2F1 (E2F transcription factor 1)
    7d
    Salmonella vector creates de novo parvovirus that reduces solid tumors and forms antitumor immune memory. (PubMed, Cell Rep Med)
    Intravenous injection of VDS produces the same responses as an intratumoral injection, and outperforms direct injection of H-1 parvovirus (H-1PV), which minimally affects immune responses and tumor volume. Combining bacteria and OVs creates a therapy that activates the immune system, generates antitumor immunity, and provides a promising platform for treating solid tumors.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    ParvOryx (parvovirus H-1)
    7d
    Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Northwell Health | Initiation date: Dec 2026 --> Jan 2026
    Trial initiation date
    |
    albumin-bound paclitaxel
    8d
    MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Ohio State University Comprehensive Cancer Center
    New trial